BioAge Therapeutics Raises $350M Series C

BioAge Therapeutics

Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.

$350M

Series C

Valuation

$4.3B

Headquarters

South San Francisco, CA

Employees

240

Sector

Healthcare

About the Funding

BioAge Therapeutics has successfully raised $350M in a Series C funding round, bringing their total valuation to $4.3B. This significant investment will fuel the company's mission to advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies.

Use of Funds

Advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies

Company Overview

Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.

Key Investors

• Genentech Ventures
• Gilead Sciences
• Andreessen Horowitz Bio Fund
• Jeff Bezos

Founders

• Dr. Sarah Longevity
• Dr. James Youth

Previous Rounds

Series B

$180M

2024-03-10

Series A

$85M

2023-09-22

Seed

$28M

2022-06-15

Market Impact

This funding round positions BioAge Therapeutics as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.